Cellmat Therapeutics announced on the 10th that it has decided to acquire 2 million shares of Etrial, a cosmetics wholesale and retail company. The acquisition amount is 1 billion KRW, and the shareholding ratio after acquisition will be 50.48%.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
